FLT3 and acute myeloid leukemia: The current standard of care for NKt-AML treatment includes induction chemotherapy with the 7 + 3 regimen with the addition of the FLT3 inhibitor Midostaurin based on the prolonged overall survival reported for FLT3-mutated AML treated with Midostaurin compared to control patient group [25].